Accession Number: | 0001209191-23-025286 |
Date: | 2023-04-19 |
Issuer: | TRACON PHARMACEUTICALS, INC. (TCON) |
Original Submission Date: |
PELLETIER SAUNDRA L
C/O TRACON PHARMACEUTICALS, INC.
4350 LA JOLLA VILLAGE DRIVE, SUITE 800
SAN DIEGO, CA 92122
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
DIRECTOR STOCK OPTION (RIGHT TO BUY) | 1.82 | 2023-04-19 | deemed execution date | A | 18,000 (a) | 2033-04-18 | common stock 18,000 | $1.82 | 18,000 | direct |
ID | footnote |
---|---|
f1 | the shares subject to the option shall vest and become exercisable on the earlier of the first anniversary of the grant date set forth in column 3 above or the date of the next annual meeting of the company's stockholders, subject to the optionee's continuous service (as defined in the company's 2015 equityincentive plan (the "plan")) and accelerated on the closing of a change of control (as defined in the plan). |